Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in IDH1-or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia ( AML) - a Multicenter Cohort Study

被引：0

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Shimony, Shai ^{[2
]}

Shallis, Rory M. ^{[3
]}

Liu, Yiwen ^{[4
]}

Schaefer, Eva Johanna ^{[5
]}

Zeidan, Amer M. ^{[6
,7
]}

Goldberg, Aaron D. ^{[1
]}

Stein, Eytan M. ^{[1
]}

Marcucci, Guido ^{[8
]}

Lindsley, R. Coleman ^{[9
]}

Chen, Evan C. ^{[5
]}

Ramos, Jorge ^{[10
]}

Stein, Anthony Selwyn ^{[11
]}

DeAngelo, Daniel J. ^{[12
]}

Neuberg, Donna S. ^{[4
]}

Stone, Richard M. ^{[12
]}

Ball, Brian J. ^{[10
]}

Stahl, Maximilian ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Harvard Med Sch, DanaFarber Canc Inst, Dept Med Oncol, Boston, MA USA

[3] Yale Univ, Sect Hematol, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[4] DanaFarber Canc Inst, Dept Data Sci, Boston, MA USA

[5] Dana Farber Canc Inst, Med Oncol, Boston, MA USA

[6] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA

[7] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[8] City Hope Natl Med Ctr & Beckman Res Inst, Dept Hematol Malignancies Translat Sci, Gehr Family Ctr Leukemia Res, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] City Hope Canc Ctr, Duarte, CA USA

[11] City Hope Natl Med Ctr, Duarte, CA USA

[12] Dana Farber Canc Inst, Boston, MA USA

[13] Dana Farber Inst, Boston, MA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-174283

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Intensive Induction Chemotherapy Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in NPM1-Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study
Bewersdorf, Jan Philipp
Shimony, Shai
Shallis, Rory M.
Liu, Yiwen
Schaefer, Eva Johanna
Zeidan, Amer M.
Goldberg, Aaron D.
Stein, Eytan M.
Marcucci, Guido
Lindsley, Coleman
Chen, Evan C.
Ramos, Jorge
Stein, Anthony Selwyn
DeAngelo, Daniel J.
Neuberg, Donna S.
Stone, Richard M.
Ball, Brian J.
Stahl, Maximilian
BLOOD, 2023, 142
[2] Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study
Bewersdorf, Jan Philipp
Shimony, Shai
Shallis, Rory M.
Liu, Yiwen
Berton, Guillaume
Schaefer, Eva J.
Zeidan, Amer M.
Goldberg, Aaron
Stein, Eytan
Marcucci, Guido
Bystrom, Rebecca P.
Lindsley, R. Coleman
Chen, Evan C.
Ramos, Jorge
Stein, Anthony
Pullarkat, Vinod
Aldoss, Ibrahim
DeAngelo, Daniel J.
Neuberg, Donna S.
Stone, Richard M.
Garciaz, Sylvain
Ball, Brian
Stahl, Maximilian
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (08) : 1640 - 1643
[3] Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States
Vachhani, Pankit
Abbas, Jonathan A.
Flahavan, Evelyn M.
Ma, Esprit
Xu, Tao
Jin, Huan
Montez, Melissa
Huang, Weize
Gershon, Anda
Ku, Grace
Flores, Brannon
Onishi, Maika
Bui, Cat N.
Donnellan, William
BLOOD, 2021, 138
[4] Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax
Croden, Jennifer
Marvin-Peek, Jennifer
Konopleva, Marina
Borthakur, Gautam
Daver, Naval
Abbas, Hussein A.
Takahashi, Koichi
Sasaki, Koji
Garcia-Manero, Guillermo
Jain, Nitin
Pemmaraju, Naveen
Short, Nicholas J.
Hammond, Danielle
Jabbour, Elias
Masarova, Lucia
Chien, Kelly S.
Issa, Ghayas C.
Montalban-Bravo, Guillermo
Yilmaz, Musa
Maiti, Abhishek
Valero, Yesid Alvarado
Kornblau, Steven M.
Ravandi, Farhad
Kantarjian, Hagop
Kadia, Tapan M.
Dinardo, Courtney D.
BLOOD, 2024, 144 : 6126 - 6128
[5] Real World Data on Clinical Outcomes of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated With Hypomethylating Agents (HMA) Plus Shorter Duration of Venetoclax (VEN) at a General Hospital
Khan, Hina
Yohannan, Binoy
Cervoni-Curet, Frances
Rios, Adan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S262 - S262
[6] Correlative Biomarkers of Response to Venetoclax (VEN) in Combination with Chemotherapy or Hypomethylating Agents (Hma) in Elderly Untreated Patients with Acute Myeloid Leukemia (AML)
Chyla, B.
Popovic, R.
Potluri, J.
Hayslip, J.
Huang, X.
Mabry, M.
Bhathena, A.
ANNALS OF HEMATOLOGY, 2017, 96 : S84 - S85
[7] Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
Bewersdorf, Jan Philipp
Shimony, Shai
Shallis, Rory M.
Liu, Yiwen
Berton, Guillaume
Schaefer, Eva J.
Zeidan, Amer M.
Goldberg, Aaron D.
Stein, Eytan M.
Marcucci, Guido
Bystrom, Rebecca P.
Lindsley, R. Coleman
Chen, Evan C.
Perez, Jorge Ramos
Stein, Anthony
Pullarkat, Vinod
Aldoss, Ibrahim
DeAngelo, Daniel J.
Neuberg, Donna S.
Stone, Richard M.
Garciaz, Sylvain
Ball, Brian
Stahl, Maximilian
BLOOD ADVANCES, 2024, 8 (18) : 4845 - 4855
[8] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
Dian Jin
Haoguang Chen
Jingsong He
Yi Li
Gaofeng Zheng
Yang Yang
Yi Zhao
Jing Le
Wenxiu Shu
Donghua He
Zhen Cai
Targeted Oncology, 2024, 19 : 237 - 249
[9] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
Jin, Dian
Chen, Haoguang
He, Jingsong
Li, Yi
Zheng, Gaofeng
Yang, Yang
Zhao, Yi
Le, Jing
Shu, Wenxiu
He, Donghua
Cai, Zhen
TARGETED ONCOLOGY, 2024, 19 (02) : 237 - 249
[10] Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) plus Venetoclax (Ven) Initiation plus /- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
Shallis, Rory Michael
Weiss, Julian
Winer, Eric S.
Badar, Talha
Swaroop, Alok
Doukas, Peter
Geramita, Emily
Le, Henry
Agarwal, Sonal
Merl, Man Yee
Im, Annie
Abaza, Yasmin
Litzow, Mark R.
Podoltsev, Nikolai A.
BLOOD, 2022, 140 : 8921 - 8922

← 1 2 3 4 5 →